March 14th, 2015
DAPT ‘Approaching the Point of Diminishing Returns’?
Larry Husten, PHD
After a myocardial infarction (MI), patients remain at high risk for recurrent events. The precise role of dual antiplatelet therapy (DAPT) to lower this risk has been the subject of considerable disagreement. Now a new study offers fresh evidence that prolonged DAPT can lower risk over a long period, but only at the cost of […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?